Elsevier

Neuroscience Letters

Volume 665, 5 February 2018, Pages 246-251
Neuroscience Letters

Research article
Effects of the antidepressant mirtazapine and zinc on nicotinic acetylcholine receptors

https://doi.org/10.1016/j.neulet.2017.12.016Get rights and content

Highlights

  • The ACh-current mediated by muscle nAChRs was inhibited by mirtazapine.

  • Potentiation of ACh-current by zinc was minor in the presence of mirtazapine.

  • Mirtazapine inhibited α7 nAChRs in hippocampal CA1 stratum radiatum interneurons.

  • The inhibitory effects of mirtazapine depended on membrane potential.

Abstract

Nicotinic acetylcholine receptors (nAChRs) and zinc are associated with regulation of mood and related disorders. In addition, several antidepressants inhibit muscle and neuronal nAChRs and zinc potentiates inhibitory actions of them. Moreover, mirtazapine (a noradrenergic, serotonergic and histaminergic antidepressant) inhibits muscarinic AChRs and its effects on nAChRs are unknown. Therefore, we studied the modulation of muscle α1β1γd nAChRs expressed in oocytes and native α7-containing nAChRs in hippocampal interneurons by mirtazapine and/or zinc, using voltage-clamp techniques. The currents elicited by ACh in oocytes (at −60 mV) were similarly inhibited by mirtazapine in the absence and presence of 100 μM zinc (IC50 ∼15 μM); however, the ACh-induced currents were stronger inhibited with 20 and 50 μM mirtazapine in the presence of zinc. Furthermore, the potentiation of ACh-induced current by zinc in the presence of 5 μM mirtazapine was 1.48 ± 0.06, and with 50 μM mirtazapine zinc potentiation did not occur. Interestingly, in stratum radiatum interneurons (at −70 mV), 20 μM mirtazapine showed less inhibition of the current elicited by choline (Ch) than at 10 μM (0.81 ± 0.02 and 0.74 ± 0.02 of the Ch-induced current, respectively). Finally, the inhibitory effects of mirtazapine depended on membrane potential: 0.81 ± 0.02 and 0.56 ± 0.05 of the control Ch-induced current at −70 and −20 mV, respectively. These results indicate that mirtazapine interacts with muscle and neuronal nAChRs, possibly into the ion channel; that zinc may increase the sensitivity of nAChRs to mirtazapine; and that mirtazapine decreases the sensitivity of nAChRs to zinc.

Introduction

Nicotinic acetylcholine receptors (nAChRs) are pentameric proteins that belong to the superfamily of Cys-loop ligand-gated ion channels. Muscle nAChRs are formed with α1, β1, γ or ε, and δ subunits; whereas neuronal nAChRs are composed of the combination of α2-α10 and β2-β4, which may be assembled as heteromeric nAChRs, or of only one subunit such as homomeric α7 nAChRs [[1], [2], [3]]. nAChRs are widely distributed in the organism, in muscle endplate mediating fast neurotransmission; whereas in the nervous system they mediate fast neurotransmission as well as modulation of transmitter release [[1], [2]]. They are involved in physiological and pathological roles such as skeletal muscle contraction, learning, memory, cognition, congenital myasthenic syndromes, Alzheimer’s disease, epilepsy, depressive disorders, and drug addiction [[4], [5], [6], [7]].

The functioning of nAChRs is modulated by a wide variety of substances interacting in allosteric sites including cations, local anesthetics, antidepressants, among others [[8], [9], [10], [11]]. Particularly, a common feature of different categories of antidepressants, including tricyclics and inhibitors of monoamine uptake, is the modulation of cholinergic signaling by inhibiting both nAChRs [[8], [12], [13], [14], [15], [16]] and muscarinic AChRs [[17], [18], [19]]. These facts strengthen the idea that cholinergic signaling is intimately associated with major depression disorder [[20], [21]].

In the case of mirtazapine – an antidepressant that inhibits norepinephrine, serotonin and histamine receptors [22] – there is one report on cholinergic activity in guinea pig urinary bladder smooth muscle, in which muscarinic AChRs are competitively inhibited by this antidepressant [19].

Interestingly, the divalent cation zinc is found throughout the brain, especially in the cerebral cortex and the hippocampus [23]. This cation allosterically interacts with nAChRs and can potentiate or inhibit them, depending on zinc concentration and receptor subunit composition [[24], [25], [26], [27]]. On other hand, zinc deficiency has been associated with depressive disorders [[28], [29], [30]]. Accordingly, zinc enhances the effect of several antidepressants both in animal models of depression and in depressive patients, and it also enhances inhibitory effects of fluoxetine and bupropion on nAChRs more strongly than the antidepressant alone [[31], [32], [33], [34], [35], [36]]. In this regard, the aim of this work was to study the pharmacological actions of mirtazapine on muscle and α7 nAChRs hippocampal interneurons, in the absence and presence of zinc.

Section snippets

Materials and methods

All experimental procedures were carried out in accordance with the National Institute of Health Guide for Care and Use of Laboratory Animals and were approved by the Institutional Animal Care Committee of the Universidad Nacional Autónoma de México, with an effort to minimize the number of animals used and their suffering.

Results

Initially, when 100 μM ACh or 100 μM zinc were applied to non-injected oocytes, or when mirtazapine or zinc were applied to injected Xenopus oocytes expressing α1β1γδ nAChRs, no measurable ion currents were detected.

Discussion

Our findings showed that mirtazapine inhibited muscle nAChRs with an IC5O of ∼15 μM. This value is in the same order as that of other structurally different antidepressants, such as fluoxetine, imipramine, nefazodone, paroxetine or venlafaxine (with an IC5O in the range of 5.6 − 24 μM), suggesting a common mode of action and affinity on muscle nAChRs [[14], [46]].

Interestingly, fluoxetine, in addition to treating depression, has been also used for treating congenital myasthenic syndrome,

Conflict of interest

The authors declare no conflict of interest.

Acknowledgements

This work was supported by the Dirección General de Asuntos del Personal Académico, UNAM (DGAPA grants IN201313 and IN205016) to J.G-C; E.V.G. was a postdoctoral fellow from DGAPA, UNAM. We thank to Patricia Villalobos for technical assistance, Martín García-Servín for his assistance in taking care of the rats, Leopoldo González-Santos for helping with the statistical analysis, and Jessica González Norris for editing the manuscript.

References (60)

  • M. Siwek et al.

    Decreased serum zinc concentration during depressive episode in patients with bipolar disorder

    J. Affect Disord.

    (2016)
  • M.P. Cunha et al.

    Interaction of zinc with antidepressants in the tail suspension test. Prog. Neuropsychopharmacol

    Biol. Psychiatry

    (2008)
  • Q. Ding et al.

    Zinc and imipramine reverse the depression-like behavior in mice induced by chronic restraint stress

    J. Affect. Disord.

    (2016)
  • U. Doboszewska et al.

    Antidepressant activity of fluoxetine in the zinc deficiency model in rats involves the NMDA receptor complex

    Behav, Brain Res.

    (2015)
  • J. García-Colunga et al.

    Interaction of bupropion and zinc with neuronal nicotinic acetylcholine receptors

    Neuropharmacology

    (2011)
  • J.J. López et al.

    Dual effects of a 2- benzylquinuclidinium derivative on α7-containing nicotinic acetylcholine receptors in rat hippocampal interneurons

    Neurosci. Lett.

    (2015)
  • E. Vázquez-Gómez et al.

    Bupropion induced inhibition of α7 nicotinic acetylcholine receptors expressed in heterologous cells and neurons from dorsal raphe nucleus and hippocampus

    Eur. J. Pharmacol.

    (2014)
  • H. Zhu et al.

    Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome

    Exp. Neurol.

    (2015)
  • S. Barbosa-Méndez et al.

    Dose- and time-dependent effects of mirtazapine on the expression of cocaine-induced behavioral sensitization in rats

    Psychiatry Res.

    (2017)
  • R. Moaddel et al.

    Sub-anesthetic concentrations of (R, S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors

    Eur. J. Pharmacol.

    (2013)
  • R.G. Hunter et al.

    Regulation of the nicotinic receptor α7 subunit by chronic stress and corticosteroids

    Brain Res.

    (2010)
  • F.J. Barrantes

    Structural basis for lipid modulation of nicotinic acetylcholine receptor function

    Brain Res. Rev.

    (2004)
  • B.I. Kalappa et al.

    The dual effect of PNU-120596 on α7 nicotinic acetylcholine receptor channels

    Eur. J. Pharmacol.

    (2013)
  • M. Kaniakova et al.

    Different effects of lobeline on neuronal and muscle nicotinic receptors

    Eur. J. Pharmacol.

    (2014)
  • E.X. Albuquerque et al.

    Mammalian nicotinic acetylcholine receptors: from structure to function

    Physiol. Rev.

    (2009)
  • C. Bouzat et al.

    Nicotinic acetylcholine receptors at the single-channel level

    Br. J. Pharmacol.

    (2017)
  • C. Deflorio et al.

    Fluoxetine prevents acetylcholine-induced excitotoxicity blocking human endplate acetylcholine receptor

    Muscle Nerve

    (2014)
  • H.O. Kalkman et al.

    Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders

    Cell. Mol. Life Sci.

    (2016)
  • J. Wang et al.

    Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors

    Br. J. Pharmacol.

    (2017)
  • J. García-Colunga et al.

    Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac)

    Proc. Natl. Acad. Sci. U. S. A.

    (1997)
  • View full text